Evidence map›Paper›PMID 28106077›Full record

ArticleCell research2017

Mesenchymal stem cell transplantation in tight-skin mice identifies miR-151-5p as a therapeutic target for systemic sclerosis.

Chider Chen, Dandan Wang, Alireza Moshaverinia, Dawei Liu, Xiaoxing Kou, Wenjing Yu, Ruili Yang, Lingyun Sun, Songtao Shi

Abstract read
In one paragraph

Article in Cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. ASC-expressing pyroptotic extracellular vesicles alleviate sepsis by protecting B cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  19. Article
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chider ChenDepartment of Anatomy and Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA 19104, USA.
Dandan WangDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu 210008, China.
Alireza MoshaveriniaDivision of Advanced Prosthodontics, Weintraub Center for Reconstructive Biotechnology, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Dawei LiuDepartment of Anatomy and Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA 19104, USA.
Xiaoxing KouDepartment of Anatomy and Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA 19104, USA.
Wenjing YuDepartment of Anatomy and Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA 19104, USA.
Ruili YangDepartment of Anatomy and Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA 19104, USA.
Lingyun SunDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu 210008, China.
Songtao ShiDepartment of Anatomy and Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA 19104, USA.

Funding

Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application)P30AR069619 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI LOUIS J SOSLOWSKY · 2016 to 2026
$9.1M
TRAINING PROGRAM/RHEUMATIC DISEASEST32AR007442 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI BEHRENS, EDWARD M, MERKEL, PETER A · 1986 to 2018
$5.8M
OSTEOGENIC MECHANISMS OF SHEDR01DE017449 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHI, SONGTAO · 2007 to 2017
$3.5M
GINGIVA DERIVED MSCS: ROLE IN IMMUNOMODULATION AND TISSUE REGENERATIONR01DE019932 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LE, ANH D, SHI, SONGTAO · 2009 to 2013
$2.8M
FAS Controls Exosome-Mediated miRNA Transfer in MSC-Based TherapyR00DE025915 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · 2019 to 2021
$732k
Epigenetic Regulation of Mesenchymal Stem Cell Transplantation in AgingR03DE028026 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · 2019 to 2020
$324k
FAS Controls Exosome-Mediated miRNA Transfer in MSC-Based TherapyK99DE025915 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · 2016 to 2017
$142k
NIAMS NIH HHS P30 AR069619NIAMS NIH HHS T32 AR007442NIDCR NIH HHS K99 DE025915NIDCR NIH HHS R00 DE025915NIDCR NIH HHS R01 DE017449NIDCR NIH HHS R01 DE019932NIDCR NIH HHS R03 DE028026
6 · The paper itself

Abstract

Systemic sclerosis (SSc), an autoimmune disease, may cause significant osteopenia due to activation of the IL4Rα/mTOR pathway. Mesenchymal stem cell transplantation (MSCT) can ameliorate immune disorders in SSc via inducing immune tolerance. However, it is unknown whether MSCT rescues osteopenia phenotype in SSc. Here we show that MSCT can effectively ameliorate osteopenia in SSc mice by rescuing impaired lineage differentiation of the recipient bone marrow MSCs. Mechanistically, we show that donor MSCs transfer miR-151-5p to the recipient bone marrow MSCs in SSc mice to inhibit IL4Rα expression, thus downregulating mTOR pathway activation to enhance osteogenic differentiation and reduce adipogenic differentiation. Moreover, systemic delivery of miR-151-5p is capable of rescuing osteopenia, impaired bone marrow MSCs, tight skin, and immune disorders in SSc mice, suggesting that miR-151-5p may be a specific target for SSc treatment. Our finding identifies a previously unrecognized role of MSCT in transferring miRNAs to recipient stem cells to ameliorate osteopenia via rescuing a non-coding RNA pathway.

Indexed as

Mesenchymal Stem Cell TransplantationMolecular Targeted TherapyAdenoviridaeAdipogenesisAnimalsBone Diseases, MetabolicBone Marrow CellsCell DifferentiationCell LineageExosomesFemaleHumansMesenchymal Stem CellsMiceMice, Inbred C57BLMice, Mutant Strainsemt protein-tyrosine kinaseMicroRNAsMIRN151a microRNA, humanMIRN151 microRNA, mouseProtein-Tyrosine KinasesReceptors, Interleukin-4TOR Serine-Threonine Kinases

Identifiers

PMID28106077
PMCPMC5385608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.